Patent classifications
C07H13/04
Polymorphs of LNnT
A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2Θ angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2Θ angles, are provided.
Microorganisms and methods for producing sialylated and N-acetylglucosamine-containing oligosaccharides
The invention provides compositions and methods for engineering bacteria to produce sialylated and N-acetylglucosamine-containing oligosaccharides, and the use thereof in the prevention or treatment of infection.
Microorganisms and methods for producing sialylated and N-acetylglucosamine-containing oligosaccharides
The invention provides compositions and methods for engineering bacteria to produce sialylated and N-acetylglucosamine-containing oligosaccharides, and the use thereof in the prevention or treatment of infection.
CRYSTAL OF ALKALI METAL N-ACETYLNEURAMINATE ANHYDRATE, AND PROCESS FOR PRODUCING SAME
According to the present invention, a crystal of an alkali metal N-acetylneuraminate anhydrate, and a process for producing a crystal of an alkali metal N-acetylneuraminate anhydrate, comprising adding or adding dropwise a solvent selected from the group consisting of alcohols and ketones to an aqueous N-acetylneuraminic acid solution containing an alkali metal-containing compound and having a pH of 3.0 to 9.0 to precipitate a crystal of an alkali metal N-acetylneuraminate anhydrate, and collecting the crystal of an alkali metal N-acetylneuraminate anhydrate from the aqueous solution, can be provided.
QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION
Provided are compounds that can inhibit pathogenic, bacterial metabolite production and conjugates of the same. Also provided are pharmaceutical compositions comprising the same and methods of using the same.
SPRAY-DRIED LACTO-N-FUCOPENTAOSE
Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of at least one lacto-N-fucopentaose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.
AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.
AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.
Fluorinated N-acetyl glucosamine analogs and xylose derivatives
The present disclosure relates to analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, inflammation, cancer and a central nervous system injury.
Fluorinated N-acetyl glucosamine analogs and xylose derivatives
The present disclosure relates to analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, inflammation, cancer and a central nervous system injury.